Physician profile
Hojun Yoo
NPI 1528048055
$2,681.59
in general payments reported to CMS, 2019-2025
24 companies · $415 in 2025
The $415 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $230 · 2021: $244 · 2022: $271 · 2023: $401 · 2024: $557 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,372.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $380.36 | 2019-2025 | |
| Medtronic, INC. | $342.05 | 2024-2025 | Symplicity G3, Ffrangio, Reveal Linq |
| Amgen INC. | $276.17 | 2019-2024 | Repatha |
| Abiomed | $271.45 | 2023-2024 | Impella |
| Abbott Laboratories | $255.16 | 2019-2025 | Aveir, Assurity |
| Boston Scientific Corporation | $163.03 | 2019-2023 | Watchman Access System |
| Sanofi-Aventis U.S. LLC | $158.74 | 2019-2023 | |
| Pfizer INC. | $152.78 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $122.40 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $72.41 | 2021-2023 | Verquvo |
| Astrazeneca Pharmaceuticals Lp | $65.94 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $62.39 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $56.82 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.09 | 2022-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $40.79 | 2022-2023 | Camzyos, Eliquis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, Ltd. | $38.93 | 2022-2023 | Arcalyst |
| Amryt Pharma Holdings Ltd | $30.30 | 2021 | |
| Novo Nordisk INC | $29.71 | 2021-2025 | Wegovy |
| Tactile Systems Technology INC | $28.52 | 2025 | Flexitouch Plus, Nimbl |
| Regeneron Healthcare Solutions, INC. | $26.59 | 2019 | |
| W. L. Gore & Associates, INC. | $23.72 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.73 | 2019 | |
| Esperion Therapeutics, INC. | $14.40 | 2021 | |
| Astellas Pharma US INC | $11.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hojun Yoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.